Country

Clinical trials in China

Active obesity and GLP-1 studies with at least one location in China.

326active studies

170recruiting now

26countries represented

201largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Overweight, ObesityCondition

Eloralintide, PlaceboTreatment

Australia, Belgium187 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07392190See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

Peripheral Arterial DiseaseCondition

Orforglipron, PlaceboTreatment

Argentina, Australia161 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07223593See eligibility →

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Overweight, ObesityCondition

Eloralintide, PlaceboTreatment

Argentina, China157 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07282600See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

Osteoarthritis, Overweight or ObesityCondition

Eloralintide, PlaceboTreatment

Argentina, Belgium152 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07353931See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

Urinary Incontinence,StressCondition

Orforglipron, PlaceboTreatment

Canada, China136 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07202884See eligibility →

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Sleep Apnea, Obstructive, ObesityCondition

Eloralintide, PlaceboTreatment

Australia, Brazil115 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07369011See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

OsteoarthritisCondition

Orforglipron, PlaceboTreatment

Canada, China88 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07153471See eligibility →

Recruiting nowPhase 1

Phase 1 Clinical Study of MWN105 Injection in Participants With Overweight or Obesity

Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)Condition

MWN105 1, MWN105 2Treatment

China1 locations

Shanghai Minwei Biotechnology Co., LtdSponsor

Updated 2026-09-08 · NCT07803809See eligibility →

Recruiting nowPhase 2

A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight

Obesity, OverweightCondition

BI 3034701, Placebo matching BI 3034701Treatment

Australia, Canada54 locations

Boehringer IngelheimSponsor

Updated 2026-09-03 · NCT07662122See eligibility →

Recruiting nowPhase 2

Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus (T2DM)Condition

MWN109 1, MWN109 2Treatment

China1 locations

Shanghai Minwei Biotechnology Co., LtdSponsor

Updated 2026-09-03 · NCT07801820See eligibility →

Recruiting nowPhase 3

Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)

Dementia, Mild, Mild Cognitive ImpairmentCondition

Mazdutide, PlaceboTreatment

China8 locations

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolSponsor

Updated 2026-09-02 · NCT07083154See eligibility →

Recruiting nowPhase 3

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

Overweight, ObesityCondition

Cagrilintide, SemaglutideTreatment

Australia, Austria121 locations

Novo Nordisk A/SSponsor

Updated 2026-08-31 · NCT07253285See eligibility →

Recruiting nowPhase 3

A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)

Knee Osteoarthritis, ObesityCondition

Ecnoglutide Injection, placebo with matching volumeTreatment

China1 locations

Hangzhou Sciwind Biosciences Co., Ltd.Sponsor

Updated 2026-08-31 · NCT07734311See eligibility →

Recruiting nowPhase 1

A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity

Type 2 Diabetes Mellitus Combined With Overweight or ObesityCondition

TQF3250 capsules, TQF3250 placeboTreatment

China12 locations

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Sponsor

Updated 2026-08-28 · NCT07747857See eligibility →

Recruiting nowPhase 1, Phase 2

A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity

Overweight and/or Obesity, Weight ManagementCondition

ecnoglutide tablets, placebo with matching dosageTreatment

China1 locations

Hangzhou Sciwind Biosciences Co., Ltd.Sponsor

Updated 2026-08-28 · NCT07243171See eligibility →

Recruiting nowNot applicable

OverStitch NXT Endoscopic Suture System

Weight LossCondition

OverStitch NXT Endoscopic Suture SystemTreatment

China1 locations

Boston Scientific CorporationSponsor

Updated 2026-08-28 · NCT07276815See eligibility →

Recruiting nowPhase 3

A Study of XW003 in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure Therapy

OSA - Obstructive Sleep Apnea, ObesityCondition

XW003 injection, placebo with matching volumeTreatment

China1 locations

Hangzhou Sciwind Biosciences Co., Ltd.Sponsor

Updated 2026-08-28 · NCT07387094See eligibility →

Recruiting nowPhase 3

A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy

OSA - Obstructive Sleep Apnea, ObesityCondition

XW003 injection, placebo with matching volumeTreatment

China1 locations

Hangzhou Sciwind Biosciences Co., Ltd.Sponsor

Updated 2026-08-28 · NCT07434050See eligibility →

Recruiting nowPhase 3

A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus

Obesity, OverweightCondition

Elecoglipron, PlaceboTreatment

China, Hong Kong49 locations

AstraZenecaSponsor

Updated 2026-08-27 · NCT07775404See eligibility →

Recruiting nowNot applicable

Orbera365 Intragastric Balloon System (Abbreviated as'Orbera365')

Weight LossCondition

Treatment groupTreatment

China1 locations

Boston Scientific CorporationSponsor

Updated 2026-08-27 · NCT07195708See eligibility →

Recruiting nowPhase 1

Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or Obesity

Drug Drug Interaction (DDI), Pharmacokinetics and PharmacodynamicsCondition

UBT251, Metformin hydrochlorideTreatment

China1 locations

The United Bio-Technology (Hengqin) Co., Ltd.Sponsor

Updated 2026-08-25 · NCT07785934See eligibility →

Recruiting nowPhase 3

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Belgium, Brazil117 locations

Eli Lilly and CompanySponsor

Updated 2026-08-24 · NCT06672549See eligibility →

Recruiting nowPhase 3

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

Obesity or OverweightCondition

Placebo, EnicepatideTreatment

Argentina, Australia195 locations

Hoffmann-La RocheSponsor

Updated 2026-08-14 · NCT07351045See eligibility →

Recruiting nowPhase 3

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

Obesity or Overweight, Type 2 Diabetes MellitusCondition

Placebo, EnicepatideTreatment

Argentina, Australia193 locations

Hoffmann-La RocheSponsor

Updated 2026-08-14 · NCT07351058See eligibility →

Recruiting nowPhase 3

A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes

Obesity, OverweightCondition

Enicepatide, PlaceboTreatment

China18 locations

Hoffmann-La RocheSponsor

Updated 2026-08-13 · NCT07670416See eligibility →

Recruiting nowPhase 3

A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects

Chronic Management of Body WeightCondition

HRS9531 Tablet, HRS9531 Tablet PlaceboTreatment

China2 locations

Fujian Shengdi Pharmaceutical Co., Ltd.Sponsor

Updated 2026-08-13 · NCT07670884See eligibility →

Recruiting nowNot applicable

Fecal Microbiota Transplantation for Obese Women With Polyendocrine Metabolic Ovarian Syndrome

PCOS (Polycystic Ovary Syndrome)Condition

oral Fecal Microbiota Transplantation, PlaceboTreatment

China1 locations

Shanghai Changzheng HospitalSponsor

Updated 2026-08-12 · NCT07746635See eligibility →

Recruiting nowPhase 3

A Study of DA-302168S in Participants With Overweight/Obesity

Overweight and ObesityCondition

DA-302168S, DA-302168STreatment

China1 locations

Chendu DIAO Pharmaceutical Group CO., LTD.Sponsor

Updated 2026-08-06 · NCT07629544See eligibility →

Recruiting nowNot applicable

Cognitive Effects of Hesperidin in Overweight/Obese Older Adults

Cognitive Dysfunction, Overweight and ObesityCondition

HesperidinTreatment

China1 locations

Min HouSponsor

Updated 2026-08-06 · NCT07750223See eligibility →

Recruiting nowPhase 3

AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Obesity, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Australia, China92 locations

Novo Nordisk A/SSponsor

Updated 2026-08-04 · NCT07571109See eligibility →

Recruiting nowPhase 3

A Study of BGM0504 in Early T2DM With Obesity

Type 2 Diabetes (T2DM)Condition

BGM0504, semaglutideTreatment

China1 locations

BrightGene Bio-Medical Technology Co., Ltd.Sponsor

Updated 2026-08-04 · NCT07743983See eligibility →

Recruiting nowPhase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS9531 Injection in Adolescents With Obesity

Overweight and ObesityCondition

HRS9531 injection；Placebo, HRS9531 injection；PlaceboTreatment

China1 locations

Fujian Shengdi Pharmaceutical Co., Ltd.Sponsor

Updated 2026-07-31 · NCT07559136See eligibility →

Recruiting nowNot applicable

Transcutaneous Auricular Vagus Nerve Stimulation for Poor Weight-Loss Response to Incretin Receptor Agonists

Obesity & OverweightCondition

transcutaneous auricular vagus nerve stimulation, ShamTreatment

China1 locations

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolSponsor

Updated 2026-07-31 · NCT07619989See eligibility →

Recruiting nowPhase 1

Phase Ib Study of Efsubaglutide Alfa Injection in Obese Adolescents

Adolescence ObesityCondition

Efsubaglutide Alfa 5 mg QW, Efsubaglutide Alfa 10 mg QWTreatment

China5 locations

Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.Sponsor

Updated 2026-07-30 · NCT07693426See eligibility →

Recruiting nowNot applicable

Researching the Useful of Barb Suture in Obese Patients Undergoing Posterior Cervical Surgery

Cervical Spinal Stenosis, Posterior Cervical Spine SurgeryCondition

posterior cervical surgeryTreatment

China1 locations

Xijing HospitalSponsor

Updated 2026-07-30 · NCT05895968See eligibility →

Recruiting nowNot applicable

Bariatric Surgery Combined With GLP-1RA: A Multicenter Study.

ObesityCondition

BS-GLP1RA group, BS groupTreatment

China7 locations

China-Japan Friendship HospitalSponsor

Updated 2026-07-29 · NCT07732738See eligibility →

Recruiting nowPhase 3

A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

Type 2 Diabetes MellitusCondition

Elecoglipron, SemaglutideTreatment

Argentina, Australia201 locations

AstraZenecaSponsor

Updated 2026-07-14 · NCT07662213See eligibility →

Recruiting nowPhase 3

AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Obesity, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Australia, China80 locations

Novo Nordisk A/SSponsor

Updated 2026-07-13 · NCT07571005See eligibility →

Recruiting nowNot applicable

Using Single and Combined Nudge Strategies to Promote Healthier Beverage Intake Among College Students

Obesity, Food SelectionCondition

choice architecture, choice architectureTreatment

China1 locations

Nanjing Medical UniversitySponsor

Updated 2026-07-07 · NCT07625969See eligibility →

Recruiting nowNot applicable

The Intervention of Obesity in Children With Prader-Willi Syndrome Using Prebiotics and Probiotics

Prader-Willi SyndromeCondition

probiotics including B. lactis B420, B. lactis HN019, B. animalis Bb-12, L. rhamnosus GG, Prebiotics with galactomannan and oligofructoseTreatment

China1 locations

Children's Hospital of Fudan UniversitySponsor

Updated 2026-07-06 · NCT05791604See eligibility →

Recruiting nowNot applicable

Efficacy and Safety of Akkermansia Muciniphila AKM Lab-01 for Overweight and Obesity

Overweight , ObesityCondition

AKM Lab-01, PlaceboTreatment

China1 locations

Moon (Guangzhou) Biotechnology Co., Ltd.Sponsor

Updated 2026-06-29 · NCT07331974See eligibility →

Recruiting nowNot applicable

Assessment of the Effects and Safety of Spermidine Supplementation on Blood Lipids and Body Weight in Overweight or Obese Individuals With Hyperlipidemia

Obesity & Overweight, HyperlipidemiaCondition

Spermidine, PlaceboTreatment

China1 locations

Shanghai 10th People's HospitalSponsor

Updated 2026-06-23 · NCT07662330See eligibility →

Recruiting nowPhase 1

Drug-drug Interaction Study of ZT002 Injection in Overweight and Obese Participants

Overweight,ObesityCondition

ZT002 injection, metformin, warfarin, ZT002 injection, rosuvastatin, digoxinTreatment

China1 locations

Beijing QL Biopharmaceutical Co.,LtdSponsor

Updated 2026-06-22 · NCT07550816See eligibility →

Recruiting nowNot applicable

Real-World Case Registry Study on Obesity

Obesity & Overweight, Obesity (Disorder)Condition

Intervention not listedTreatment

China1 locations

Hubei Hospital of Traditional Chinese MedicineSponsor

Updated 2026-06-12 · NCT07448090See eligibility →

Recruiting nowNot applicable

Effect of Lidocaine Through Gastric Tube on PONV

PONVCondition

Lidocaine, Normal Saline (0.9% NaCl)Treatment

China1 locations

General Hospital of Ningxia Medical UniversitySponsor

Updated 2026-06-11 · NCT07643298See eligibility →

Recruiting nowNot applicable

GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity

ObesityCondition

LSG-Semaglutide group, LSG-Mazdutide groupTreatment

China1 locations

China-Japan Friendship HospitalSponsor

Updated 2026-06-08 · NCT07633639See eligibility →

Recruiting nowPhase 2

GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)

Cerebral Small Vessel DiseaseCondition

GLP-1 receptor agonistTreatment

China, Hong Kong2 locations

Chinese University of Hong KongSponsor

Updated 2026-06-05 · NCT05356104See eligibility →

Recruiting nowPhase 3

Phase III Study of HRS-7535 for Hypertension With Overweight or Obesity

Hypertension With Overweight or ObesityCondition

HRS-7535, PlaceboTreatment

China2 locations

Shandong Suncadia Medicine Co., Ltd.Sponsor

Updated 2026-06-05 · NCT07528027See eligibility →

Recruiting nowNot applicable

Transcutaneous Auricular Vagus Nerve Stimulation for Poor Weight-Loss Response to Lifestyle Intervention

Obesity & OverweightCondition

transcutaneous auricular vagus nerve stimulation, ShamTreatment

China1 locations

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolSponsor

Updated 2026-06-05 · NCT07630597See eligibility →

Recruiting nowPhase 2, Phase 3

Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia

Atypical Endometrial Hyperplasia, Fertility IssuesCondition

Intensive Lifestyle Intervention (ILI), Megestrol Acetate 160 MG Oral TabletTreatment

China1 locations

Xiaojun ChenSponsor

Updated 2026-06-04 · NCT05316493See eligibility →

Recruiting nowNot applicable

Laparoscopic Versus Open Surgery for Colon Cancer With Visceral Obesity

Colonic NeoplasmsCondition

Laparoscopic surgery, Open surgeryTreatment

China1 locations

Second Affiliated Hospital, Zhejiang University, School of MedicineSponsor

Updated 2026-06-03 · NCT07314996See eligibility →

Recruiting nowPhase 2

Efficacy of a GLP-1/FGF21 Dual Agonist for Treating PCOS

PCOS (Polycystic Ovary Syndrome)Condition

GLP-1/FGF21 dual agonist (HEC88473)Treatment

China1 locations

Shanghai Zhongshan HospitalSponsor

Updated 2026-05-29 · NCT07616037See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity

Overweight, ObesityCondition

IBI362, PlaceboTreatment

China1 locations

Innovent Biologics (Suzhou) Co. Ltd.Sponsor

Updated 2026-05-27 · NCT07469800See eligibility →

Recruiting nowNot applicable

Research on the Efficacy and Safety of Targeted Suprachiasmatic Nucleus Electrical Stimulation for Improving Metabolic Disorders in Patients With Stable Bipolar Disorder Comorbid With Obesity

Bipolar Disorder (BD)Condition

Temporal Interference Stimulation, Sham Temporal Interference Stimulation Arm DescriptionTreatment

China1 locations

First Affiliated Hospital of Zhejiang UniversitySponsor

Updated 2026-05-27 · NCT07589647See eligibility →

Recruiting nowNot applicable

Smartwatch-based Intervention for Cardiovascular Health (SWITCH)

Prehypertension, Borderline DyslipidemiaCondition

Smartwatch-Based Multi-Faceted Behavioral Intervention Model Led by Exercise and Dietary Interventions, Supported by Primary Medical Staff, Along with the Distribution of Health Education Manuals, Face-to-face health education sessionsTreatment

China3 locations

Beijing Anzhen HospitalSponsor

Updated 2026-05-14 · NCT07372729See eligibility →

Recruiting nowPhase 1

A Study of SHR-2906 Injection in Healthy Subjects With a Single Dose and in Obese Patients With Multiple Doses

Obesity, OverweightCondition

SHR-2906 Injection, SHR-2906 Injection PlaceboTreatment

China1 locations

Beijing Suncadia Pharmaceuticals Co., LtdSponsor

Updated 2026-05-14 · NCT07280936See eligibility →

Recruiting nowNot applicable

Genetics of Obesity in Chinese Youngs

Obesity, Metabolic SyndromeCondition

Intervention not listedTreatment

China1 locations

Shanghai Jiao Tong University School of MedicineSponsor

Updated 2026-05-12 · NCT01084967See eligibility →

Recruiting nowNot applicable

Weight Loss Via Intelligent Guidance in Patients With Coronary Heart Disease and Obesity: a Randomized Clinical Trial

CHD, Overweight or ObeseCondition

dietary regulation and structured exercise trainingTreatment

China1 locations

Guangdong Provincial People's HospitalSponsor

Updated 2026-05-12 · NCT07514611See eligibility →

Recruiting nowNot applicable

Time Restricted Eating in Childhood Obesity (TRECO)

Childhood ObesityCondition

Calorie-restricted diet (CRD), Time-restricted eating (TRE)Treatment

China2 locations

Xiaoyan ShiSponsor

Updated 2026-05-08 · NCT06583447See eligibility →

Recruiting nowPhase 4

Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes

Type 2 Diabetes, Diabetes With Diabetic Autonomic Neuropathy (Diagnosis)Condition

GLP-1 Receptor AgonistsTreatment

China1 locations

The First Affiliated Hospital with Nanjing Medical UniversitySponsor

Updated 2026-04-30 · NCT07558863See eligibility →

This page shows the first 60 studies. Use the full search to filter all matches.

Related countries

United States1,107 Canada158 France110 Spain98 Germany95

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.